Revenue

At CES 2026, Jinxin Technology unveiled NAMI INSIGHT One, AI-powered learning glasses aiming to revolutionize education. But can it overcome the hurdles?

With new funding, Major Medical Devices is advancing a novel AAA repair device that uses arm access, promising safer procedures and wider patient eligibility.

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

Amid rising regulatory pressure, dxFeed's flawless performance in a critical industry-wide disaster recovery test sets a new benchmark for data reliability.

Manhattan Associates embeds agentic AI and advanced simulation tools into its platform, promising to boost retail productivity, profits, and customer loyalty.

Over 450 elite runners from 50 nations converge on Apalachee Regional Park this Saturday, cementing Tallahassee's status as a world-class sports hub.

Newly-formed materials giant Magnera reports Q1 results on Feb 5. Investors eye its path to profitability while the industry watches for key market signals.

NCR Voyix is launching a new AI-driven, microservices-based platform designed to help restaurants combat labor shortages and meet rising customer expectations.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

The brokerage closed deals with 150 lenders in 2025, adding 48 new partners. How did this strategy help them navigate a complex real estate landscape?

A new report reveals 10 proven ways to fix the critical mental health gap for trafficking survivors, as 75% call it their most urgent need.

The strategic merger creates a vertically integrated supplier, combining advanced forming with precision machining to target aerospace, defense, and automotive.

With a massive $200M Series A and a promising Phase 2 drug, new biotech AirNexis aims to reshape the multi-billion dollar COPD treatment landscape.

With 11 straight quarters of growth and a focus on 'Physical AI,' lidar leader Ouster is set to detail its ambitious strategy for institutional investors.

A new partnership makes Eli Lilly's powerful AI models available to smaller firms via Revvity's platform, aiming to accelerate innovation with federated learning.

After a major business sale, Elutia is launching NXT-41x, an antibiotic biomatrix designed to combat the high rate of infection in breast reconstruction.

Rigetti Computing pushes back its Cepheus-1-108Q launch to Q1 2026, a move that rattled investors but underscores the quantum industry's tough race for fidelity.

With its first MASH drug a success, Madrigal aims to redefine treatment by combining it with a newly licensed Pfizer asset. Is this the future?